<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02738632</url>
  </required_header>
  <id_info>
    <org_study_id>ID-TAH-301</org_study_id>
    <nct_id>NCT02738632</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients</brief_title>
  <official_title>Randomized, Double-Blind, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Hydrochlorothiazide Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients Not Controlled by Telmisartan/Amlodipine Combination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, Double-Blind, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of&#xD;
      Telmisartan/Amlodipine/Hydrochlorothiazide Combination in Comparison with&#xD;
      Telmisartan/Amlodipine Combination for Essential Hypertension Patients not Controlled by&#xD;
      Telmisartan/Amlodipine Combination&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of sitting systolic blood pressure</measure>
    <time_frame>From baseline at week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of sitting systolic blood pressure</measure>
    <time_frame>From baseline at week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of sitting diastolic blood pressure</measure>
    <time_frame>From baseline at week 2 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ratio of subjects who get normalized blood pressure</measure>
    <time_frame>at week 2 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>at week 2 and 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Telmisartan/Amlodipine+Hydrochlorothiazide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan/Amlodipine combination drug and Hydrochlorothiazide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan/Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan/Amlodipine combination drug and Placebo for Hydrochlorothiazide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan/Amlodipine+Hydrochlorothiazide</intervention_name>
    <description>Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg 1 Tab.QD&#xD;
Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg 1 Tab.QD</description>
    <arm_group_label>Telmisartan/Amlodipine+Hydrochlorothiazide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan/Amlodipine</intervention_name>
    <description>Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg Placebo 1 Tab.QD&#xD;
Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg Placebo 1 Tab.QD</description>
    <arm_group_label>Telmisartan/Amlodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Hydrochlorothiazide</intervention_name>
    <arm_group_label>Telmisartan/Amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 19 years old or above Koreans living in Korea&#xD;
&#xD;
          2. Patients with uncontrolled essential hypertension at screening time(Visit 1)&#xD;
&#xD;
               -  Naïve: 160 mmHg ≤ sitSBP &lt; 200 mmHg&#xD;
&#xD;
               -  Use antihypertensive drugs:140 mmHg ≤ sitSBP &lt; 200 mmHg&#xD;
&#xD;
          3. Patients with uncontrolled hypertension after Telmisartan/Amlodipine 40/5mg treatment&#xD;
             for 6 weeks at randomization(Visit 2)&#xD;
&#xD;
             - 140 mmHg ≤ sitSBP &lt; 200 mmHg&#xD;
&#xD;
          4. Patients who agreed to participate in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Test results showing the following values at screening time(Visit 1)&#xD;
&#xD;
               -  The change of mean sitSBP ≥ 20 mmHg or sitDBP ≥ 10 mmHg on target arm between 1st&#xD;
                  and 2nd measurement&#xD;
&#xD;
               -  screening time(Visit 1), time of randomization(Visit 2): sitDBP ≥ 120 mmHg&#xD;
&#xD;
          2. Patients with secondary blood pressure or suspected of secondary blood pressure (for&#xD;
             example,aortic coarctation, primary aldosteronism, renal artery stenosis,&#xD;
             pheochromocytoma)&#xD;
&#xD;
          3. -Patients with congestive heart failure(NYHA class III~IV)&#xD;
&#xD;
               -  Patients with unstable angina or myocardial infarction or valvular heart disease&#xD;
                  within 6 months prior to study entry&#xD;
&#xD;
               -  Patients who have severe ventricular tachycardia, atrial fibrillation, atrial&#xD;
                  flutter or clinically significant arrhythmia&#xD;
&#xD;
          4. Patients who have history of cerebrovascular disease as cerebral infarction, cerebral&#xD;
             hemorrhage within 6 months prior to study entry&#xD;
&#xD;
          5. Type I Diabets Mellitus or Type II Diabetes Mellitus with HbA1c &gt; 9%&#xD;
&#xD;
          6. Patients who have history of severe or malignant retinopathy within 6 months prior to&#xD;
             study entry&#xD;
&#xD;
          7. Patients who suspected of Renal dysfunction that may affect the absorption,&#xD;
             distribution, metabolism or excretion (Serum Creatinine :&gt; 2mg/dL ), gastrointestinal,&#xD;
             haematological, liver disease (AST or ALT &gt; 2.5 times of upper limit of normal range)&#xD;
&#xD;
          8. Patients who should be administered antihypertensive drugs other than clinical trial&#xD;
             medication(Diuretics, β-blockers, ACE inhibitors, Angiotensin II Receptor Blocker,&#xD;
             Calcium Channel Blockers, α-blockers, Renin Inhibitors, Vasodilators)&#xD;
&#xD;
          9. Patients who should be administered medications prohibited for concomitant use during&#xD;
             study period&#xD;
&#xD;
         10. Patients who are dependent on drugs or alcohol&#xD;
&#xD;
         11. Patients with surgical and medical disease that may affect the absorption,&#xD;
             distribution, metabolism or excretion&#xD;
&#xD;
         12. Patients with hypersensitivity to the components of investigational drug.&#xD;
&#xD;
         13. Patients with hypersensitivity to Sulfonamide&#xD;
&#xD;
         14. Patients with anuria&#xD;
&#xD;
         15. Patients with hypercalcemia, hyponatremia/hypokalemia&#xD;
&#xD;
         16. Patients with Addison's disease&#xD;
&#xD;
         17. Patients who have hereditary problems such as galactose intolerance, Lapp lactase&#xD;
             deficiency, or glucose-galactose malabsorption&#xD;
&#xD;
         18. Patients with any chronic or accute inflammation disease needed to chronic&#xD;
             inflammation therapy&#xD;
&#xD;
         19. History of malignant tumor including leukemia, lymphoma within 5 years&#xD;
&#xD;
         20. Patients taking other clinical trial drugs within 30 days from the time of visit for&#xD;
             screening&#xD;
&#xD;
         21. Pregnancy, breast-feeding, or child-bearing potential Patients&#xD;
&#xD;
         22. Patients who are judged unsuitable to participate in this study by investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>April 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <last_update_submitted>November 22, 2016</last_update_submitted>
  <last_update_submitted_qc>November 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Telmisartan amlodipine combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

